Opportunities lie in strategic investment formulation, identifying cost-effective locations for conducting trials, understanding global trial trends, and analyzing trial success rates. Insights into ...

Patients with SSc were linked to an increased risk for hematological malignancies, specifically B-cell malignancies.

Mycophenolate mofetil treatment in patients with limited cutaneous systemic sclerosis is linked to a reduced need for escalation of vasoactive or vasodilator therapies for vascular complications.

Nutritional issues such as ARFID are highly prevalent among patients with SSc and can lead to poor outcomes and other ...

In addition to PH, columnist Jolie Lizana faces a possible scleroderma diagnosis, as coexisting conditions continue to ...

VANCOUVER, BC / ACCESS Newswire / January 21, 2026 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT) is pleased to report final results from a preclinical pig study ...

Cabaletta Bio, Inc. (Nasdaq: CABA) laid out an ambitious 2026 roadmap centered on advancing rese-cel, its experimental CAR T ...

Building on the success of (Vascular Injury in Systemic Diseases: Current Concepts and Future Perspectives, we are pleased to ...

The global, double-blinded phase 3 study enrolled 165 patients aged between 12 and 75 years and measured the time to onset ...

FDA grants Breakthrough Therapy status to NVS's ianalumab for Sjogren's disease with plans for global filings starting in ...

The Commonwealth Transportation Board at its Jan. 6 meeting in Richmond awarded a $218.9 million contract to Triton ...